Interventional Oncology Market is Expected to Reach $2.9 billion | MarketsandMarkets.
12 avr. 2023 09h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, April 12, 2023 (GLOBE NEWSWIRE) -- The interventional oncology industry is expected to experience significant growth in the coming years, as new technologies and treatments are developed...
Global Interventional Oncology Devices Market Report 2023: Players Include Boston Scientific, Medtronic, Terumo, and Philips Volcano
30 mars 2023 10h18 HE
|
Research and Markets
Dublin, March 30, 2023 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Criterium, Inc. Announces Formation of New Oncology Research Consortium for Genito-Urinary Indications
26 janv. 2023 09h30 HE
|
Criterium Inc.
SARATOGA SPRINGS, N.Y., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators...
The Worldwide Interventional Oncology Industry is Expected to Reach $2.9 Billion by 2028
24 nov. 2022 08h08 HE
|
Research and Markets
Dublin, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Size, Share & Industry Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer,...
Global Interventional Oncology Market Analysis Report 2022: A $2.11 Billion Market by 2026 - Forecasts to 2029
23 nov. 2022 06h08 HE
|
Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Interventional Oncology...
Global Interventional Oncology Market Expected to Generate a Revenue of $3,313.5 Million, Rising at a CAGR of 6.7% during the Analysis Timeframe from 2021 to 2028 [170-Pages] | Exclusively Available by Research Dive
23 mars 2022 09h01 HE
|
Research Dive
New York, USA, March 23, 2022 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global interventional oncology market is envisioned to generate a revenue of $3,313.5...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
07 mars 2022 17h37 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
Global Interventional Oncology Devices Market, 2021-2030: Opportunities in the Emergence of Local Companies in Asia-Pacific and the Middle East and Africa
06 déc. 2021 06h43 HE
|
Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Market Analysis and Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering. The global...
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
01 nov. 2021 00h15 HE
|
HUTCHMED (China) Limited
— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57%...
FDA Approves Phase II Kidney Cancer Therapy Study
13 sept. 2021 18h41 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...